Ilya Pharma announces FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity
Uppsala, May 4, 2022: Ilya Pharma AB (the Company), a clinical stage immunotherapy company today announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the Company is immediately accelerating preparations for large adaptive Phase 2 study, designed as a pivotal trial. ILP100-Topical is a first-in-class immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity. These patients have weeks to months delayed healing following surgery and a substantially increased risk of serious wound complications.Robert D. Galiano, MD, FACS